Together, we can transform the future of cancer care.
Tracking early stage breast cancer with ultrasensitive ctDNA
Information for patients with breast cancer
Monitoring therapy response with ultrasensitive ctDNA across cancer types
Ultrasensitive ctDNA detection in early-stage lung cancer
Personalis is transforming the development of next-generation therapies.
NeXT Dx is an advanced test that looks at all the genes in your cancer cells to help match effective targeted treatments specific to your cancer. Our personalized test can also help identify clinical trials to target your disease.
Tumor Profiling
Mutations in cancer-associated genes reported by the NeXT Dx test can help identify new therapies.
Our team of expert genetic counselors handpick clinical trials at a location nearest to you and based on your individual condition.
You’re just three steps away from more personalized cancer care
See if NeXT Dx testing is right for your condition. Tumor profiling tests are indicated for late-stage cancers to help expand treatment options.
Our team will gather your samples and analyze them in our state-of-the-art laboratory. We scan for hundreds of mutations and biomarkers in your tissue sample.
Your doctor will review your results with you to make an informed treatment plan personalized to your cancer.
In the NeXT Dx test, sequencing is performed on samples taken from your tumor tissue and blood.
Once your doctor places an order for the NeXT Dx test, Personalis will work with your hospital’s pathology department to obtain a sample of your tumor. We will also coordinate the collection of a blood sample (either at your doctor’s office or in your own home). Your samples will be sent to the Personalis Clinical Laboratory, where they will be processed and analyzed. A report will be sent back to your doctor who ordered your test. Your doctor will be in touch to review the results of your test with you.
The NeXT Dx test can be ordered by your doctor. For questions about ordering the NeXT Dx test, please contact Personalis at clientservices@personalis.com or give us a call at +1 (855) 373-7978. We’re available Monday to Friday from 9:00 am to 5:00 pm (PST).
Medicare and some commercial plans cover NeXT Dx for advanced cancer patients. At Personalis, we work with all health insurance plans. If we are considered to be out-of-network for your health insurance plan, we will apply your in-network benefits to any out-of-pocket costs that you may incur.
NeXT Dx is a next-generation sequencing (NGS) based laboratory developed test (LDT) for cancer patients with solid tumors. NeXT Dx analyzes the whole exome to report small nucleotide variants (SNVs), small insertions and deletions (indels), copy number alterations (CNAs), and gene fusions in select cancer-related genes as well as MSI and exome-wide “true” TMB. Alterations detected by NeXT Dx are reported with associated therapeutics or matched clinical trials. Genomic findings are not prescriptive or conclusive for labeled use of any specific therapeutic product. Tests may result in no reportable alterations and/or no associated therapeutics or clinical trials. A negative result does not rule out the presence of an alteration. NeXT Dx is performed in the CLIA/CAP accredited Personalis Clinical Laboratory. NeXT Dx was developed and performance characteristics determined by the Personalis Clinical Laboratory. NeXT Dx has not been cleared or approved by the United States Food and Drug Administration (FDA). The Personalis Clinical Laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing.
Saldivar, J. S., Harris, J., Ayash, E., Hong, M., Tandon, P., Sinha, S., Hebron, P. M., Houghton, E. E., Thorne, K., Goodman, L. J., Li, C., Marfatia, T. R., Anderson, J., Morra, M., Lyle, J., Bartha, G., & Chen, R. (2023). Analytic validation of NeXT Dx™, a comprehensive genomic profiling assay. Oncotarget, 14, 789–806. https://doi.org/10.18632/oncotarget.28490
PRO-1148-v1 (v1.0)
